Maravai LifeSciences Financial Statements
NASDAQ: MRVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Maravai LifeSciences revenue and earnings
In fiscal 2025, Maravai LifeSciences generated $185.7 million in revenue, down 28.3% from fiscal 2024, its first annual decline since 2024. Maravai LifeSciences reported a net loss of $130.8 million, compared with a loss of $144.8 million a year earlier. Gross margin was 18.3% (down from 41.8%) and operating margin -115.9%.
Diluted earnings per share came in at -$0.90. Over the last 5 fiscal years, MRVI's revenue has grown at a -8.1% compound annual rate (a contraction).
Summary generated from market data by MetaCap's automated system. Methodology
Maravai LifeSciences income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Revenue | 185.74M | 259.19M | 288.94M | 883.00M | 799.24M | 284.10M | 143.14M |
| Revenue growth (YoY) | -28.34% | -10.30% | -67.28% | +10.48% | +181.33% | +98.48% | — |
| Cost of Revenue | 151.75M | 150.88M | 148.74M | 168.96M | 140.56M | 79.65M | 66.85M |
| Gross Profit | 33.99M | 108.31M | 140.20M | 714.04M | 658.68M | 204.45M | 76.29M |
| Operating Expenses | 249.26M | 343.93M | 171.85M | 139.83M | 104.03M | 84.55M | 52.30M |
| Research & Development | 17.40M | 19.22M | 17.28M | 18.37M | 15.22M | 9.30M | 3.63M |
| Selling, General & Admin | 145.12M | 161.77M | 151.39M | 129.26M | 100.06M | 94.25M | 48.35M |
| Operating Income | -215.27M | -235.62M | -31.65M | 574.22M | 554.64M | 119.90M | 23.99M |
| Interest Expense | 26.99M | 47.70M | 45.89M | 20.41M | 30.26M | 30.74M | 29.96M |
| Other Income (Expense) | -4.15M | -2.34M | -1.34M | -358.00K | 279.00K | 126.00K | 118.00K |
| Pretax Income | -234.97M | -261.48M | 617.74M | 551.47M | 530.76M | 81.70M | -5.85M |
| Income Tax | -4.21M | -1.86M | 756.11M | 60.81M | 61.52M | 2.88M | -652.00K |
| Net Income | -130.77M | -144.85M | -119.03M | 220.21M | 182.04M | 88.97M | -4.47M |
| Net Income growth (YoY) | — | — | -154.05% | +20.97% | +104.60% | — | — |
| EPS (Basic) | -0.90 | -1.05 | -0.90 | 1.67 | 1.59 | 7.43 | -0.03 |
| EPS (Diluted) | -0.90 | -1.05 | -0.90 | 1.67 | 1.56 | 2.36 | -0.03 |
| Shares Outstanding (Basic) | 144.36M | 137.91M | 131.92M | 131.54M | 114.79M | 10.35M | 253.92M |
| Shares Outstanding (Diluted) | 144.36M | 137.91M | 131.92M | 255.32M | 257.80M | 28.91M | 253.92M |
| EBITDA | -191.71M | -214.76M | -18.75M | 581.78M | 561.06M | 125.50M | 27.80M |
| Gross Margin | 18.30% | 41.79% | 48.52% | 80.87% | 82.41% | 71.96% | 53.30% |
| Operating Margin | -115.89% | -90.91% | -10.95% | 65.03% | 69.40% | 42.20% | 16.76% |
| Net Margin | -70.41% | -55.89% | -41.19% | 24.94% | 22.78% | 31.32% | -3.12% |
This table shows 7 annual periods of Maravai LifeSciences's income statement, from FY 2025 back to FY 2019, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow MRVI's reporting calendar. What is a income statement?